Liquidia (NASDAQ:LQDA) Insider Sells $207,932.48 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,301 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $207,932.48. Following the sale, the insider directly owned 177,957 shares of the company’s stock, valued at $5,068,215.36. This represents a 3.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79.
• On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64.

Liquidia Stock Down 3.1%

Shares of LQDA traded down $0.86 during midday trading on Tuesday, reaching $26.81. 3,092,611 shares of the company were exchanged, compared to its average volume of 5,078,983. The stock has a 50-day moving average price of $63.40 and a 200-day moving average price of $61.76. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.49) earnings per share. Research analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Liquidia during the 2nd quarter worth approximately $29,694,000. Eversept Partners LP increased its holdings in Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Seven Fleet Capital Management LP increased its holdings in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares during the last quarter. Finally, Pale Fire Capital SE raised its position in shares of Liquidia by 2.4% in the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after purchasing an additional 8,985 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Citigroup reissued a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Lifesci Capital downgraded shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Wednesday, August 12th. HC Wainwright lowered their price target on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a report on Friday, October 2nd. Wall Street Zen downgraded shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Needham & Company LLC dropped their price target on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating on the stock in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Hold” and an average target price of $83.69.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).